Xiretsa develops Antiinfective Conjugated Electrolytes (ACEs), a novel platform for broad-spectrum antimicrobial agents. This technology shows activity against Gram-positive and Gram-negative bacteria, as well as certain pathogenic fungi. The modular design allows for rapid derivatization to address unmet needs in infectious disease therapy and combat antimicrobial resistance.
Funding
Funding not disclosed
Founders
Product
Problem
The rise of antibiotic-resistant bacteria poses a significant threat to modern medicine, rendering common infections increasingly difficult and costly to treat. Current antibiotic development pipelines are insufficient to address the growing number of resistant strains, potentially leading to a post-antibiotic era where routine surgeries and treatments become life-threatening.
Solution
Xiretsa is developing Antiinfective Conjugated Electrolytes (ACEs), a novel class of broad-spectrum antibiotics designed to combat multi-drug resistant bacteria and certain pathogenic fungi. The ACE platform's modular design allows for rapid derivatization and simple synthesis, creating a flexible approach to address evolving resistance mechanisms. ACEs exhibit activity against both Gram-positive and Gram-negative bacteria, demonstrating negligible cross-resistance with existing antibiotics, which may extend the drug's marketable lifetime and reduce treatment failures. This technology offers a potential solution to the critical unmet need for new antibiotics effective against superbug infections.
Target Audience
The primary target audience includes healthcare providers, hospitals, and pharmaceutical companies seeking novel therapeutic options to combat antibiotic-resistant infections.
Features
- Broad-spectrum activity against Gram-positive and Gram-negative bacteria, as well as certain pathogenic fungi
- Modular design enabling rapid derivatization and simple synthesis for tailored applications
- Negligible cross-resistance to existing antibiotics, potentially reducing the risk of treatment failures
- Addresses critical unmet needs in infectious disease therapy